Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2225-2230

  Hegele, Axel ^a   Dalpke, Alexander ^a   Barth, Peter ^a   Varga, Zoltan ^a   Heeg, Klaus ^a   Hofmann, Rainer ^a   Olbert, Peter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bladder neoplasm; CpG ODN; Immunotherapy; Subcutaneous animal model

Indexed keywords

BACTERIAL DNA; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CPG ISLAND; FEMALE; HISTOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; URINARY BLADDER NEOPLASMS;

EID: 4444324183     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Holmang S, Hedelin H, Anderstrom C and Johansson SL: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153: 1823-1826, 1995.
2. Heney NM: Natural history of superficial bladder cancer. Urol Clin North Am 19: 429-433, 1992.
3. Bouffiuox CH: Intravesical chemoprophylaxis of superficial transitional cell carcinoma of the bladder. When should the drug be given? In: Superificial Bladder Cancer. Part B, EORTC (Schröder FH, Richards B, eds.). New York, Alan R Liss, 1995: pp 47-55.
4. Oosterlinck W, Lobel B, Jackse G, Malmstrom PU, Stockle M and Strenberg C: Guidelines on bladder cancer. EAU Recommendations 2001. Prog Urol 12: 1161-1163, 2002.
5. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205-1209, 1991.
6. Martinez-Pineiro JA: BCG versus chemtherapy in T1G3 bladder carcinoma. Proceedings of the First Lübeck Symposium on Bladder Cancer. Oxford: The Medicine Foundation 75-85, 1997.
7. Böhle A, Jocham D and Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169: 90-95, 2003.
8. Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG and Flad HD: Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53-58, 1990.
9. Schamhart DH, de Boer EC, de Reijke TM and Kurth K: Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol 37 Suppl 3: 16-23, 2000.
10. Sander B, Damm O, Gustafsson B, Andersson U and Hakansson L: Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin. J Urol 156: 536-541, 1996.
11. Zlotta AR, Van Vooren JP, Denis O, Drowart A, Daffe M, Lefevre P, Schandene L, De Cock M, De Bruyn J, Vandenbussche P, Jurion F, Palfliet K, Simon J, Schulman CC, Content J and Huygen K: What are the immunologically active components of bacille Calmette-Guerin in therapy of superficial bladder cancer? Int J Cancer 87: 844-852, 2000.
12. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T et al: Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 72: 955-962, 1984.
13. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M and Klinman DM: Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167: 3555-3558, 2001.
14. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000.
15. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H and Heeg K: CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 27: 2340-2344, 1997.
16. Heeg K and Zimmermann S: CpG DNA as a Th1 trigger. Int Arch Allergy Immunol 121: 87-97, 2000.
17. Wagner H: Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 73: 329-368, 1999.
18. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, Krug A, Rothenfusser S, Endres S and Hartmann G: Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunology 169: 3892-3899, 2002.
19. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA and Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549, 1995.
20. Dalpke A, Zimmermann S and Heeg K: CpG DNA in the prevention and treatment of infections. BioDrugs 16: 419-431, 2002.
21. Summerhaynes IC and Franks LM: Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst (Bethesda) 62: 1017-1023, 1979.
22. Wooldridge JE, Ballas Z, Krieg AM and Weiner GJ: Immunostimulatory oligodeoxynucleotides containig CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89: 2994-2998, 1997.
23. Auf G, Carpentier AF, Chen L, LeClanche C and Delattre JY: Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 7: 3540, 2001.
24. Yamamoto S, Kuramoto E, Shimada S and Tokunaga T: In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 79: 866-873, 1988.
25. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O and Tokunaga T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 148: 4072-4076, 1992.
26. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann. PV and Tary-Lehmann M: Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 171: 3941-3946, 2003.
27. Baines J and Celis E: Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 9: 2693-2700, 2003.
28. Jahrsdorfer B and Weiner GJ: Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin Oncol 30: 476-482, 2003.
29. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333-335, 1994.
30. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL and Krieg AM: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164: 1617-1624, 2000.
31. Lipford GB, Sparwasser T, Zimmermann S, Heeg K and Wagner H: CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 165: 1228-1235, 2000.
32. Kranzer K, Bauer M, Lipford GB, Heeg K, Wagner H and Lang R: CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 99: 170-178, 2000.
33. Zimmermann S, Heeg K and Dalpke A: Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3′ sequence modifications. Vaccine 21: 990-995, 2003.
34. Dalpke AH, Zimmermann S, Albrecht I and Heeg K: Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 106: 102-112, 2002.
35. Verthelyi D, Gursel M, Kenney RT, Lifson JD, Liu S, Mican J and Klinman DM: CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol 170: 4717-4723, 2003.
36. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B and Klinman DM: CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168: 1659-1663, 2002.
37. Hartmann G and Krieg AM: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164: 944-953, 2000.